Search

Your search keyword '"R-CHOP-E"' showing total 2 results
Start Over Descriptor "R-CHOP-E"
2 results on '"R-CHOP-E"'

1. Successful treatment of diffuse large B-cell lymphoma with secondary hemophagocytic lymphohistiocytosis by R-CHOP-E regimen: a case report

Author

Siguo Hao, Ran Wu, Xiaohui Deng, and Liyuan Ma

Subjects
0301 basic medicine, Secondary Hemophagocytic Lymphohistiocytosis, Male, China, endocrine system, Medicine (General), medicine.medical_treatment, chemotherapy, Biochemistry, Lymphohistiocytosis, Hemophagocytic, Special Issue: Hematology, 03 medical and health sciences, 0302 clinical medicine, R5-920, Japan, immune system diseases, hemic and lymphatic diseases, medicine, Cytotoxic T cell, R-CHOP-E, case report, Humans, Hemophagocytic lymphohistiocytosis, Chemotherapy, business.industry, Biochemistry (medical), Remission Induction, fungi, Cell Biology, General Medicine, Diffuse large B-cell lymphoma, medicine.disease, musculoskeletal system, excisional biopsy, Lymphoma, Regimen, 030104 developmental biology, hemophagocytic lymphohistiocytosis, 030220 oncology & carcinogenesis, Cancer research, Lymphoma, Large B-Cell, Diffuse, Cytokine storm, business
Abstract

Hemophagocytic lymphohistiocytosis (HLH) is a rare fatal clinical syndrome characterized by a hyperinflammatory condition caused by aberrantly activated macrophages and cytotoxic T cells, resulting in a cytokine storm and organ impairment. Lymphoma, especially B-cell lymphoma in Japan, is a common trigger of secondary HLH. In China, however, most cases of HLH secondary to lymphoma occur in patients with T-cell/natural killer-cell lymphoma or Hodgkin`s lymphoma; HLH is relatively uncommon in patients with B-cell non-Hodgkin’s lymphoma. We herein describe a man with diffuse large B-cell lymphoma (DLBCL) and secondary HLH who was successfully treated by R-CHOP-E chemotherapy. All symptoms resolved and laboratory indications of HLH normalized, and complete remission of the lymphoma was achieved. This rare case highlights not only the possibility of HLH secondary to DLBCL but also the importance of early initiation of R-CHOP-E chemotherapy.

Published
2020

2. Successful treatment of diffuse large B-cell lymphoma with secondary hemophagocytic lymphohistiocytosis by R-CHOP-E regimen: a case report.

Author

Wu R, Deng X, Hao S, and Ma L

Subjects
China, Humans, Japan, Male, Remission Induction, Lymphohistiocytosis, Hemophagocytic drug therapy, Lymphoma, Large B-Cell, Diffuse complications, Lymphoma, Large B-Cell, Diffuse drug therapy
Abstract

Hemophagocytic lymphohistiocytosis (HLH) is a rare fatal clinical syndrome characterized by a hyperinflammatory condition caused by aberrantly activated macrophages and cytotoxic T cells, resulting in a cytokine storm and organ impairment. Lymphoma, especially B-cell lymphoma in Japan, is a common trigger of secondary HLH. In China, however, most cases of HLH secondary to lymphoma occur in patients with T-cell/natural killer-cell lymphoma or Hodgkin`s lymphoma; HLH is relatively uncommon in patients with B-cell non-Hodgkin's lymphoma. We herein describe a man with diffuse large B-cell lymphoma (DLBCL) and secondary HLH who was successfully treated by R-CHOP-E chemotherapy. All symptoms resolved and laboratory indications of HLH normalized, and complete remission of the lymphoma was achieved. This rare case highlights not only the possibility of HLH secondary to DLBCL but also the importance of early initiation of R-CHOP-E chemotherapy.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results